Where is ZyVersa located?
ZyVersa is located in Weston, Florida.
Where is ZyVersa incorporated?
ZyVersa is incorporated in the state of Delaware.
When did ZyVersa go public?
ZyVersa became a public company in December, 2022.
What is ZyVersa’s focus?
ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms. Our focus is on renal and inflammatory diseases which have a global total addressable market of around $14.5 billion and $65 billion, respectively. The lead candidate in our renal pipeline is Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, which mediates removal of excess renal cholesterol and lipids that damage the kidneys. VAR 200 is expected to reduce proteinuria and delay disease progression. For treatment of inflammatory diseases, ZyVersa is developing a highly differentiated monoclonal antibody that inhibits inflammasome ASC (IC 100). By targeting ASC, IC 100 potentially inhibits twelve or more types of inflammasomes, not just NLRP3. This is expected to better control inflammation in diseases that are triggered by activation of more than one type of inflammasome. Likewise, by targeting ASC, IC 100 inhibits inflammasome formation and initiation of the inflammatory cascade. IC 100 also inhibits intra- and extracellular ASC specks which amplify and propagate inflammation in inflammatory diseases. IC 100 has strong indication expansion potential in a broad range of CNS and other inflammatory diseases.
Who makes up ZyVersa’s executive management team and board of directors?
ZyVersa’s executive management team can be viewed here.
ZyVersa’s board of directors can be viewed here.
Does ZyVersa have intellectual property protections?
ZyVersa has issued & pending patents in and outside the US for both its renal and inflammatory product platforms. New filings are planned throughout the development process for each platform.
What is ZyVersa’s stock symbol, and on what exchange is it traded?
ZyVersa is traded on the NASDAQ stock exchange under the symbol ZVSA.
Who is ZyVersa’s transfer agent?
Whom do I contact with questions about my stock?
For questions about stock, please contact our transfer agent, Continental Stock Transfer & Trust. The transfer agent’s address is 1 State Street, 30th Floor, New York, NY 10004-1561, and the telephone number is 212-509-4000 or 800-509-5586.
Where can I find ZyVersa’s financial information?
ZyVersa’s financial information can be viewed here
When do Zyversa’s fiscal quarters end?
Zyversa’s fiscal quarters end on March 31, June 30, September 30, and December 31.
Does ZyVersa have a Whistle Blower Hotline?
ZyVersa has established an independently operated, anonymous, and confidential hotline for reporting suspected violations of laws, regulations, or ZyVersa policies. The hotline can be accessed 24 hours a day, 7 days a week as follows: (1) Secure Web Form at https://www.whistleblowerservices.com/ZyVersa
or (2) Secure Phone Line at 833-636-3075. For more information, please refer to ZyVersa’s Whistle Blower Policy, which can be viewed here
Who is ZyVersa’s independent auditor?
Ernst & Young LLP
One Manhattan West
401 9th Avenue
New York, NY
Who is ZyVersa’s outside legal counsel?
300 Madison Avenue, 27th Floor
New York, New York 10017-6232